AR

ARCH Venture Partners — Pre-Seed & Seed VC Firm ($1.0M–$20.0M Checks)

VC
Chicago, Illinois, United StatesProfile updated November 2026Website

ARCH Venture Partners is a Pre-Seed, Seed, Series A venture capital firm based in Chicago, Illinois, United States investing in Healthcare, Deep Tech. The firm typically writes $1.0M–$20.0M checks and has 130 portfolio companies in our records.

Check size
$1.0M–$20.0M
Portfolio
130 companies on record
Partners
13 listed
AUM
$12B
Stage
Pre-Seed, Seed, Series A
Sectors
Healthcare, Deep Tech
HQ
Chicago, Illinois, United States

Last verified: 2026-11-09

How to approach: warm intro preferred
Stage

Pre-Seed, Seed, Series A

Check Size

$1.0M – $20.0M

AUM

$12.0B

Portfolio

130+ companies

Team

13 partners

About ARCH Venture Partners

ARCH Venture Partners is a venture capital firm headquartered in Chicago, Illinois. The firm backs disruptive science companies, primarily founding and investing in early-stage life-sciences and technology companies, including companies working to prevent, detect, and cure disease. ARCH Venture Partners often builds companies alongside leading scientists and entrepreneurs.

The firm invests at the pre-seed, seed, and series A stages. Sectors of focus include healthcare, deep tech, and cell therapy. Typical check sizes range from $1.0M to $20.0M. ARCH Venture Partners has assets under management of $12B. A warm introduction is preferred when approaching the firm.

Investment Thesis

ARCH backs disruptive science and builds early-stage companies, primarily in life sciences and physical sciences. Its current focus includes companies developing technologies to prevent, detect, and cure disease.

How ARCH Venture Partners invests

ARCH Venture Partners is a vc firm based in Chicago, Illinois, United States. The firm invests at the Pre-Seed, Seed, Series A stages, with a focus on Healthcare, Deep Tech.

ARCH Venture Partners typically writes checks of $1.0M–$20.0M per investment, backed by approximately $12B in assets under management. Our records include 6 funds raised by the firm.

ARCH Venture Partners has backed 130 companies in our records, including Beam Therapeutics, Lyell Immunopharma, Halo Top.

Partners & Team

MS

Melanie Simms

Director of Operations

AH

Allison Hurst

Director of Operations

IC

Inca Coman

Venture Partner

LB

Luciana Borio

Venture Partner

ZW

Zachary Wensch

Senior Vice President of Finance

RJ

Roger Johnson

Tax Director

SK

Sean Kendall

Partner

SG

Steve Gillis

Managing Director

RK

Ross Kozarsky

Vice President, Partnerships

RN

Robert Nelsen

Managing Director

Biotech
Immunotherapy
DeepTech
SP

Specific partner not identified in source

Partner

biotech
pharma
TB

Tom Brennan

Venture Partner

EE

Elizabeth Edwards

Founder & Managing Partner

Consumer Goods
Wellness

Industry Focus

Invests In

Healthcare
Deep Tech

Funds

ARCH Venture Partners Fund VI

$350M2021
investing

ARCH Venture Partners Fund V

$300M2018
closed

ARCH Venture Partners Fund IV

$250M2015
closed

ARCH Venture Partners Fund III

$200M2012
closed

ARCH Venture Partners Fund II

$150M2009
closed

ARCH Venture Partners Fund I

$100M2006
closed

Recent Activity

Investment Track Record

ARCH Venture Partners has recorded investments in 135 portfolio companies. These include 908 Devices, Accompany Health, Aera Therapeutics, Agios Pharmaceuticals, AIRNA, Akamis Bio, Aledade, Alnylam Pharmaceuticals, Altos Labs, and Arbor Biotechnologies. The firm has also made recorded investments in several of its own venture funds, including ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund VIII Overage, L.P., ARCH Venture Fund X, L.P., and ARCH Venture Fund XI, L.P.

The firm's team includes Robert Nelsen, managing director with focus areas in biotech, immunotherapy, and deep tech, along with other partners and operations staff.

Portfolio Companies (130)

Other

BE

Beam Therapeutics

Gene Editing
LY

Lyell Immunopharma

Cell Therapy
HA

Halo Top

Health Foods
CA

Calm

Mental Fitness
AR

ArsenalBio

Cell therapy / immuno-oncology·Early-stage; listed by ARCH as a Fund XIII investment.·ARCH Venture Fund XIII

Cell therapy company developing programmable cancer treatments.

ME

Metsera

Biotech·Early-stage; listed by ARCH as a Fund XIII investment.·ARCH Venture Fund XIII

Biotechnology company; ARCH lists it as a Fund XIII investment.

XA

Xaira Therapeutics

Biotech·Early-stage; listed by ARCH as a Fund XIII investment.·ARCH Venture Fund XIII

Biotechnology company; ARCH lists it as a Fund XIII investment.

MI

Mirador Therapeutics

MO

Moleculent AB

MO

Moonwalk Biosciences

RNA-interference and epigenetic therapeutics platform focused on obesity and cardiometabolic disease

How to pitch ARCH Venture Partners
  • •Raising at Pre-Seed, Seed, Series A? You're squarely in their sweet spot.
  • •Lead with your fit in Healthcare, Deep Tech — the sectors they actively back.
  • •Size your ask to their typical $1.0M – $20.0M check.
  • •warm intro preferred
  • •Address your outreach to a specific partner, such as Melanie Simms, Director of Operations.
  • •A warm introduction beats a cold email. Get matched and request an intro.

Featured In

Browse More Investors

Fundraising resources

Frequently Asked Questions

See if ARCH Venture Partners is a match for your startup

Upload your pitch deck to see how well you match with ARCH Venture Partners and 10,000+ other investors.

Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT

Is this your profile? Request a correction or removal